Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) Target Price at $11.50

Cellebrite DI Ltd. (NASDAQ:CLBTGet Rating) has earned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.71.

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft cut their target price on Cellebrite DI from $11.00 to $10.00 in a research report on Friday, May 13th. Cowen cut their target price on Cellebrite DI from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday. Cowen cut their target price on Cellebrite DI from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday. William Blair downgraded Cellebrite DI from an “outperform” rating to a “market perform” rating in a research report on Friday. Finally, Bank of America downgraded Cellebrite DI from a “buy” rating to a “neutral” rating and cut their target price for the company from $6.50 to $6.00 in a research report on Friday.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC lifted its holdings in Cellebrite DI by 4,239.7% during the 4th quarter. Wolverine Asset Management LLC now owns 3,168 shares of the company’s stock valued at $25,000 after buying an additional 3,095 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Cellebrite DI in the 4th quarter valued at about $35,000. Josh Arnold Investment Consultant LLC bought a new stake in shares of Cellebrite DI in the 1st quarter valued at about $64,000. DGS Capital Management LLC bought a new stake in shares of Cellebrite DI in the 2nd quarter valued at about $64,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Cellebrite DI in the 1st quarter valued at about $127,000. Institutional investors own 36.75% of the company’s stock.

Cellebrite DI Price Performance

Shares of CLBT opened at $5.29 on Tuesday. The stock has a market capitalization of $997.38 million, a price-to-earnings ratio of 7.15, a price-to-earnings-growth ratio of 5.19 and a beta of 0.90. Cellebrite DI has a 1 year low of $4.10 and a 1 year high of $13.24. The business’s 50 day simple moving average is $5.31 and its 200-day simple moving average is $5.74.

About Cellebrite DI

(Get Rating)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Further Reading

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.